博瑞医药：拟注册发行不超过3亿元中期票据

Core Viewpoint - The company plans to apply for the registration and issuance of medium-term notes not exceeding 300 million yuan, with a maturity of up to 5 years, to broaden financing channels and reduce financing costs [1] Group 1 - The issuance has been approved by the company's fourth board of directors' sixth meeting and will be submitted for shareholder meeting approval [1] - The funds raised will be used for research and development investments and to supplement working capital in compliance with national laws and regulations [1]